Back to Index
Shannon M Mumenthaler, PhD
Assistant Professor of Research Medicine
Lab Director, Center For Applied Molecular Medicine
CSC 240 Health Sciences Campus Los Angeles
+1 323 442 2529


Dr. Mumenthaler is an Assistant Professor of Research Medicine at the CAMM. She received a B.S. in Genetics from UC Davis and a Ph.D. in Cellular and Molecular Pathology from UCLA. Although her primary scientific training is in cell biology, Dr. Mumenthaler applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians, and engineers to explore critical areas in cancer. Her current research interests focus on the development of tools to better understand the evolutionary dynamics of tumor progression and drug resistance with specific investigations into the influence of microenvironmental selective pressures on tumor cell behavior. Toward this goal, Dr. Mumenthaler is closely collaborating with mathematical modelers to combine novel computational platforms with diverse experimental measurements to test and refine biological hypotheses and make clinically relevant predictions.


University of California, Davis: Undergraduate Student of the Year Award, Division of Biological Sciences, 2003

University of California, Los Angeles: Hortenese Fishbaugh Memorial Scholarship, 2006-2007

University of California, Davis: Alumni Scholarship, 2000

University of California, Davis: Graduated with Honors, 2003

USC: Medical Faculty Women's Association Award, 2013

University of California, Davis: Howard Hughes Medical Institute Summer Honors Advanced Research Program (SHARP) Fellowship, 2002

Webber Foundation: Academic Scholarship, 1999-2003

National Cancer Institute: Junior Investigator Award, 2013

University of California, Los Angeles: Life Sciences Core Curriculum Teaching Assistant Honorarium Award, 2005-2006

Third Annual National Cancer Institute Physical Sciences in Oncology Center: Best Poster Award, 2012


Park SM, Lee JY, Hong S, Lee SH, Dimov IK, Lee H, Suh S, Pan Q, Li K, Wu AM, Mumenthaler SM, Mallick P, Lee LP. Dual transcript and protein quantification in a massive single cell array. Lab Chip. 2016 Oct 7; 16(19):3682-8. View in: PubMed

Lindsay D, Garvey CM, Mumenthaler SM, Foo J. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol. 2016 Aug; 12(8):e1005077. View in: PubMed

Yadav VK, Smith KS, Flinders C, Mumenthaler SM, De S. Significance of duon mutations in cancer genomes. Sci Rep. 2016; 6:27437. View in: PubMed

Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016; 6:29752. View in: PubMed

Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D. Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers. 2015 Jul; 20(5):313-22. View in: PubMed

Frieboes HB, Smith BR, Wang Z, Kotsuma M, Ito K, Day A, Cahill B, Flinders C, Mumenthaler SM, Mallick P, Simbawa E, Al-Fhaid AS, Mahmoud SR, Gambhir SS, Cristini V. Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One. 2015; 10(6):e0129433. View in: PubMed

Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET ImmunoPET for Non-Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. View in: PubMed

Mumenthaler SM, D'Antonio G, Preziosi L, Macklin P. The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: PubMed

Foo J, Leder K, Mumenthaler SM. Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013 Jan; 6(1):54-69. View in: PubMed

Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

Villablanca AC, Tenwolde A, Lee M, Huck M, Mumenthaler S, Rutledge JC. 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. View in: PubMed

Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, Kitchen CM. CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009 Apr 25; 387(1):59-66. View in: PubMed

Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW. Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008 Oct 1; 68(14):1561-9. View in: PubMed

Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. Expression of arginase II in prostate cancer. Int J Oncol. 2008 Feb; 32(2):357-65. View in: PubMed

Powered bySC CTSI